EZH2 loss promotes gastric squamous cell carcinoma.

EZH2 缺失会促进胃鳞状细胞癌的发生

阅读:7
作者:Zhang Mengsha, Zhong Ailing, Liu Hongyu, Zhao Lei, Wang Yingjie, Lu Zhenghao, Zhang Lanxin, Pan Xiangyu, Liang Zuoyu, Gao Limin, Chen Xuelan, Wang Jian, Dai Siqi, Wan Xudong, Wang Manli, Chen Jingyao, Du Jiajia, Chen Shuang, Peng Tingfa, Cai Jingyang, Chen Liuxiang, Yang Yang, Xiao Chaoxin, Yao Menglin, Xu Jing, Qin Runkuan, Yang Chan, Wu Baohong, Zhang Qi, Liu Shengzhuo, Zhao Chengjian, Deng Hongxin, Wang Yuan, Chen Lu, Hu Jiankun, Hu Bing, Yang Shengyong, Na Feifei, Guo Linjie, Liu Yu, Chen Chong
Gastric Squamous Cell Carcinoma (GSCC) is a rare but aggressive subtype of gastric cancer with unique histopathology, whose etiology remains poorly understood. Here, we perform genomics analyses of twenty GSCC samples and find that epigenetic regulation genes are among the most frequently mutated genes, including Enhancer of zeste homolog 2 (EZH2). Ezh2 loss induces squamous feature both in gastric organoids in vitro and in vivo mouse model. Ezh2 deficiency, together with Trp53 and Pten loss, both of which are also frequently mutated in GSCC, give rise to full-blown GSCC in mice. Mechanistically, we find that Ezh2 could repress the expression of Transcription factor AP-2 gamma (Tfap2c), a transcription factor with the ability to initiate epidermal squamous differentiation, through H3K27 methylation. Disruption of Tfap2c reduces the squamous characteristics of the Ezh2 loss-driven GSCC and reverses its resistance to chemo treatment. Our findings elucidate key molecular mechanisms underlying GSCC pathogenesis and identify potential therapeutic targets for this aggressive malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。